Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04049825 Active, not recruiting - Clinical trials for Relapsed or Refractory Diffuse Large B-cell Lymphoma

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Start date: November 22, 2019
Phase: Phase 1
Study type: Interventional

To investigate the tolerability and safety of OPB-111077 in combination with bendamustine and rituximab in patients with r/r DLBCL.

NCT ID: NCT04049513 Active, not recruiting - Clinical trials for Diffuse Large B-cell Lymphoma (DLBCL)

ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

ENABLE
Start date: October 11, 2019
Phase: Phase 1
Study type: Interventional

This Phase 1, single centre, open label dose escalation study aims to identify a safe dose of third-generation anti-CD19 CAR T-cells (WZTL-002) in the treatment of patients with relapsed or refractory (r/r) B-cell Non Hodgkin Lymphoma, for use in further efficacy trials. An expansion cohort will assess automated closed-system manufacture of WZTL-002 and outpatient management of participants.

NCT ID: NCT04048395 Recruiting - Follicular Lymphoma Clinical Trials

Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea

FLPOD24
Start date: July 8, 2019
Phase:
Study type: Observational

This retrospective study was proposed by the investigators to analyze treatment status and outcome in patients with early relapsed follicular lymphoma. In patients with follicular lymphoma who experienced disease progression within 24 months after initiation of treatment, the second-line therapy, stem cell transplantation, tumor response, progression free survival, and overall survival will be analyzed.

NCT ID: NCT04047797 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Start date: August 28, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with rituximab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving ixazomib and rituximab may work better in treating patients with mantle cell lymphoma compared to rituximab alone.

NCT ID: NCT04045470 Recruiting - Clinical trials for Peripheral T Cell Lymphoma

A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

Start date: December 11, 2019
Phase: N/A
Study type: Interventional

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma

NCT ID: NCT04045028 Terminated - Multiple Myeloma Clinical Trials

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start date: July 22, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).

NCT ID: NCT04044222 Recruiting - Clinical trials for Classic Hodgkin's Lymphoma

A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Start date: October 21, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies the side effects of sintilimab to see how well it works when given together with ifosfamide, carboplatin, and etoposide in treating patients with classic Hodgkin lymphoma that does not respond to first-line standard chemotherapy.

NCT ID: NCT04043845 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

Start date: February 3, 2020
Phase: Phase 1
Study type: Interventional

This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

NCT ID: NCT04043494 Recruiting - Clinical trials for Lymphoblastic Lymphoma, Childhood

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

LBL 2018
Start date: August 23, 2019
Phase: Phase 3
Study type: Interventional

Primary objectives: - Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) - Randomization R2, only patients with high risk LBL eligible: to examine, whether the probability of event-free survival (pEFS) in these patients can be improved by receiving an intensified treatment arm versus a standard treatment arm (as used in the EURO-LB 02)

NCT ID: NCT04040491 Recruiting - Clinical trials for Peripheral T-cell Lymphoma

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Start date: September 1, 2019
Phase: Phase 4
Study type: Interventional

To observe the safety, tolerability and clinical effects of PD-1, chidamide, lenalidomide and gemcitabine in the treatment of newly diagnosed and relapse/refractory peripheral T-cell lymphoma.